Search Thermo Fisher Scientific
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
BCR-ABL Monoclonal Antibody (7C6)
高级验证
This Antibody was verified by Knockout to ensure that the antibody binds to the antigen stated.
图: 1 / 12
BCR-ABL Antibody (MA1-153) in WB
Knockout of BCR was achieved by CRISPR-Cas9 genome editing using LentiArray™ Lentiviral sgRNA (Product # A32042, Assay ID CRISPR981967_LV) and LentiArray Cas9 Lentivirus (Product # A32064). Western blot analysis of BCR was performed by loading 30 µg of A-431 Wild Type (Lane 1), A-431 Cas9 (Lane 2) andA-431 BCR KO (Lane 3) whole cell extracts. The samples were electrophoresed using NuPAGE™ 3-8% Tris-Acetate Protein Gel (Product # EA0378BOX). Resolved proteins were then transferred onto a nitrocellulose membrane (Product # IB23001) by iBlot®... View More
产品信息
MA1-153
应用
建议稀释比
已发表文章
产品规格
种属反应
Human,
Mouse
已发表种属
Human
宿主/亚型
Mouse
/ IgG2a
分类
Monoclonal
类型
Antibody
克隆号
7C6
抗原
Bcr686 thyroglobulin conjugate corresponding to human BCR sequence 686-696 (SSINEEITPRRQS)
偶联物
形式
Liquid
浓度
1 mg/mL
纯化类型
Protein A
保存液
PBS with 1mg/mL BSA
内含物
0.05% sodium azide
保存条件
-20°C
运输条件
Ambient (domestic); Wet ice (international)
RRID
AB_2536861
产品详细信息
Western blot analysis of MA1-153 detects ~130-160 kDa and a 210-250 kDa protein in K562 cells. In addition to BCR-ABL, BCR and ABL are also expressed in these cells and full length BCR is also detected by the antibody. For detection purposes, non-reducing conditions resulted in enhanced detection of BCR-ABL.
靶标信息
A reciprocal translocation between chromosomes 22 and 9 produces the BCR-ABL fusion oncoprotein, which is found in patients with chronic myelogenous leukemia (CML). Although there are various versions, p210 is the most commonly found BCR-ABL form. The fusion to BCR, results in deregulated/constitutively active tyrosine kinase activity of BCR-ABL which is sufficient of oncogenic transformation of myeloid cells. Inhibition of BCR-ABL oncogenic activity by the ABL-kinase inhibitor STI-571 (also known as gleevec, imatinib) became the first and best example for successful targeted therapy of cancer, and specifically CML. In recent years, several mutations (such as the T351I mutation) were found in CML patients that resulted in STI-571 resistance and the need for additional drug development.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
生物信息学
蛋白别名: BCR/FGFR1 chimera protein; breakpoint cluster region; breakpoint cluster region homolog; Breakpoint cluster region protein; FGFR1/BCR chimera protein; Renal carcinoma antigen NY-REN-26
基因别名: 5133400C09Rik; AI561783; AI853148; ALL; BCR; BCR1; CML; D22S11; D22S662; Kiaa3017; mKIAA3017; PHL
UniProt ID: (Human) P11274, (Mouse) Q6PAJ1
Entrez Gene ID: (Human) 613, (Mouse) 110279
protein serine/threonine kinase activity
protein tyrosine kinase activity
Rho guanyl-nucleotide exchange factor activity
GTPase activator activity
protein binding
ATP binding
kinase activity
enzyme binding
nucleotide binding
guanyl-nucleotide exchange factor activity
transferase activity
G-protein modulator
negative regulation of cellular extravasation
protein phosphorylation
signal transduction
brain development
peptidyl-tyrosine phosphorylation
actin cytoskeleton organization
response to lipopolysaccharide
regulation of Rho protein signal transduction
intracellular signal transduction
inner ear morphogenesis
regulation of vascular permeability
negative regulation of neutrophil degranulation
positive regulation of GTPase activity
protein autophosphorylation
platelet-derived growth factor receptor signaling pathway
negative regulation of inflammatory response
positive regulation of phagocytosis
neuromuscular process controlling balance
regulation of small GTPase mediated signal transduction
regulation of cell cycle
negative regulation of blood vessel remodeling
phosphorylation
negative regulation of cell migration
